Day 2 Highlights of ECTRIMS 2024
Anne Helme, Head of Research at MSIF, and host Brett Drummond discuss the key takeaways unveiled on the second day of ECTRIMS 2024 in Copenhagen, as well as the value of global collaboration.
19 Syys 202423min
Day 1 Highlights of ECTRIMS 2024
ECTRIMS Vice President Bruno Stankoff highlights the most relevant insights from day one of ECTRIMS 2024 in Copenhagen, and provides a glimpse of what to expect from the ECTRIMS society in the coming ...
18 Syys 202419min
Pre-Day Highlights of ECTRIMS 2024
Listen to Romain Marignier from CHU de Lyon and host Brett Drummond discuss highlights of ECTRIMS' new Pre-Day on NMOSD, MOGAD, and other rare neurological conditions.
17 Syys 202417min
Episode 35: NMOSD and MOGAD Part II
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations...
10 Syys 202426min
Episode 35: NMOSD and MOGAD Part I
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations...
10 Syys 202420min
ECTRIMS-EAN Vaccination Consensus Statement (eanCast)
The following episode has been produced by the European Academy of Neurology (EAN) in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and has been...
4 Syys 202433min
Environmental, Genetic, and Epigenetic Risk Factors in MS
Multiple sclerosis (MS) is a complex and multifaceted neurological disorder. While MS has a genetic component, it is not a classic genetic disease. For this reason, a large amount of research has been...
15 Elo 202427min
Myelin plasticity and repair
The next major step forward in the management of MS involves finding treatments that can repair damaged myelin. If successful, it would offer the potential to start to reverse some of the symptoms exp...
23 Heinä 202440min
